Lemborexant overdose: A case report

Abstract

Rationale: Advances in sleep research have introduced medications like lemborexant, a dual orexin receptor antagonist. While effective for regulating sleep, overdoses are a concern, especially in suicide attempts. However, limited data exist on lemborexant overdose, prompting this case report to elucidate its clinical course.

Patient’s Concern: A 91-year-old Japanese woman with multiple comorbidities, including insomnia and chronic kidney disease, was admitted after ingesting 315 mg of lemborexant in a suicide attempt.

Diagnosis: Lemborexant overdose.

Interventions: Supportive care with 500 mL of Ringer’s acetate solution at the emergency room.

Outcomes: She gradually regained full consciousness with no residual deficits. Due to persistent suicidal ideation, she was transferred to a psychiatric hospital after seven days of supportive care.

Lessons: A review of four lemborexant overdose cases managed at our hospital revealed that overdoses primarily induce altered consciousness and are unlikely to cause organ dysfunction. Supportive care is generally sufficient for management. However, given the limited data, further case accumulation is needed to enhance clinical understanding.

Keywords

Lemborexant / Overdose / Poisoning / Suicidal attempt

Conflict of interest statement

The authors report no conflict of interest.

Funding

This study received no extramural funding.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: Results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 2020; 43(9):zsaa123.

[2] Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J, et al. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology (Berl) 2023; 240(4):699-711.

[3] Gotfried MH, Auerbach SH, Dang-Vu TT, Mishima K, Kumar D, Moline M, et al. Efficacy and safety of insomnia treatment with lemborexant in older adults: Analyses from three clinical trials. Drugs Aging 2024; 41(9):741-752.

[4] Yamasaki G, Ueno Y, Takahashi M, Kondo T. Fatal acute lemborexant Poisoning: An autopsy case report. Leg Med (Tokyo) 2024;71:102527.

[5] Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: But lack of benefit. F1000Res 2016;5:918.

[6] Matsumoto T. Current problems of psychiatric treatment from the point of view of prescribed-drug abuse and dependence: Benzodiazepine abuse and dependence in Japanese psychiatric patients. Jpn J Clin Psychopharmacol 2013;16:803-812.

[7] Koizumi Y, Higashitani M, Fukui S, Kodama T, Ito H, Kobayashi D. A case of barbiturate poisoning from pentobarbital in a young Japanese patient. Cureus 2023; 15(3):e36498.

[8] Tardelli VS, Bianco MCM, Prakash R, Segura LE, Castaldelli-Maia JM, Fidalgo TM, et al. Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses. Lancet Reg Health Am 2022;10:100190.